ALLMedicine™ Growth Hormone Deficiency Center

Mar 24th, 2023 - Laron dwarfism is a rare genetic disorder first reported among Israeli jewish children, subsequently about 350 cases cases have been reported worldwide. We aim to describe the clinical profile of nine children with Laron dwarfism from Institute of...

Mar 21st, 2023 - Childhood-onset craniopharyngiomas (CPs) have a high incidence of growth hormone deficiency (GHD) leading to growth failure and metabolic disorders. We aim to evaluate the benefits and risks of recombinant human growth hormone replacement therapy ...

Mar 21st, 2023 - Growth hormone deficiency (GHD) may occur in pediatric patients with central nervous system (CNS) tumors at initial tumor presentation or later as treatment-related sequelae. While it is well recognized that growth hormone (GH) has beneficial effe...

Mar 16th, 2023 - Bone is one of the main targets of hormones and endocrine diseases are frequent causes of secondary osteoporosis and fractures in real-world clinical practice. However, diagnosis of skeletal fragility and prediction of fractures in this setting co...

Mar 10th, 2023 - Kabuki syndrome (KS) is an epigenetic machinery multisystem disorder with peculiar facial gestalt and dental-oral anomalies. This report describes the case of a KS patient with congenital hyperinsulinism, growth hormone deficiency and novel hetero...

Sep 17th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present with hypopituitarism and/or hyperprolactinemia. To review the existing literature as it pertains to preoperative endocrine assessment in the work...

Mar 6th, 2023 - Growth hormone replacement has consistently shown improvements in body composition, exercise capacity, endothelial function, inflammatory biomarkers, bone mineral density, lipoprotein metabolism, and self-reported quality of Life (QOL) in patients...

Mar 1st, 2023 - The TRIIM-X trial is an expanded pilot clinical study that will evaluate a personalized combination treatment regimen for thymus regeneration. The thymus is a part of the immune system that declines markedly with age, and regenerating it may preve...

Feb 21st, 2023 - In this study, the general long-term safety and effectiveness of Sogroya (somapacitan) in adults with growth hormone deficiency (AGHD) being treated per normal clinical practice is looked into. In the study, information on side effects and how wel...

Feb 16th, 2023 - There is significant overlap between the symptoms of adult growth hormone deficiency (AGHD) and those of Gulf War Illness (GWI) such as fatigue, chronic pain, depression, anxiety, and cognitive dysfunction. AGHD is also associated with metabolic c...

Feb 8th, 2023 - GHD is the most common anterior pituitary abnormality after traumatic brain injury (TBI). It can occur as a result of either direct pituitary or indirect hypothalamic injury. Sports-related repetitive head trauma might induce pituitary dysfunction...

Nov 22nd, 2022 - The FDA approved the second interchangeable biosimilar insulin product, Eli Lilly's insulin glargine-aglr (Rezvoglar), for pediatric and adult patients with diabetes, the agency announced. Patients with diabetes and chronic kidney disease should b...

Mar 23rd, 2022 - In a study of 7,422 nursing home residents with type 2 diabetes, 17% met criteria for glycemic overtreatment and another 23% met criteria for potential overtreatment. (Journal of the American Geriatrics Society) Aeterna Zentaris announced some del...

Feb 20th, 2022 - Interim data from a long-term extension study of setmelanotide (Imcivree) for pediatric and adult patients with Bardet-Biedl Syndrome found an average BMI reduction of 14.3% from baseline and a 14.9% drop in body weight, Rhythm Pharmaceuticals ann...

Jan 24th, 2022 - Note that some links may require registration or subscription. Strained hospitals are calling potentially infectious healthcare workers back to their posts, citing the CDC's latest guidance. (Washington Post) NIAID Director Anthony Fauci, MD, said...

Sep 2nd, 2021 - The US Food and Drug Administration (FDA) has approved lonapegsomatropin (Skytrofa, Ascendis Pharma), the first weekly subcutaneous injectable growth hormone for children with growth hormone deficiency (GHD). The approval was based on the findings...